Swiss regulatory framework on fresh-cell therapy

regulatory notice · 1985

type:regulatory notice

year:1985

citation:Federal Council and cantonal action against unauthorized fresh-cell-therapy providers in Switzerland; ongoing regulatory framework administered by Swissmedic under the Transplantation Act (2004) and the Therapeutic Products Act. Cantonal-level restrictions, FMH (Swiss Medical Association) resolutions, and federal-level regulatory guidance through the 1980s contributed to the eventual prohibition of fresh-cell therapy within recognized Swiss medicine.

LINK

https://www.admin.ch/en/nsb?id=56686

SUMMARY

The Swiss regulatory framework prohibiting fresh-cell therapy of the Niehans type within recognized medicine. Federal Council communications on enforcement actions against illegal fresh-cell-therapy providers continue and represent the contemporary canonical reference for the practice's status. The prohibition framework as it exists today derives from the Transplantation Act (2004), the Therapeutic Products Act, and the Swissmedic regulatory regime; cantonal-level and federal-level restrictions through the 1980s built the trajectory toward the modern prohibition. The 1985 date is preserved here as a conventional reference point in the broader discourse on Niehans's eventual disconfirmation.

NOTES

The Swiss prohibition is the central institutional disconfirmation event in the Niehans case. The broader prohibition framework is well-documented and ongoing; federal-level enforcement actions against illegal fresh-cell-therapy providers continue and are the current canonical reference for the practice’s status within Swiss medicine. The German Wikipedia entry on Niehans summarizes the prohibition trajectory; primary regulatory documents are held in the Bundesblatt / Recueil officiel and in cantonal health-authority archives.